News | Pharmaceuticals | February 01, 2018

Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

The National Aeronautics and Space Administration (NASA) awarded a grant to evaluate Humanetics Corporation's investigational new drug, BIO 300

 

Humanetics Presents Data on Drug to Protect Cardiac Cells From Space-Like Radiation

Photo from NASA

February 1, 2018 –Humanetics Corporation (Humanetics) has recently completed two research studies funded by the National Aeronautics and Space Administration (NASA) and the National Space Biomedical Research Institute (NSBRI), which evaluated the potential of Humanetics’ investigational drug, BIO 300, to mitigate the toxicities from space-like radiation exposure.

The research tested BIO 300’s ability to protect both animal and human cells from space-like radiation exposure (e.g. protons and mixed-fields). One focus of these projects: evaluating BIO 300’s ability to protect the cardiovascular system. This is of special interest to NASA due to concern for radiation-induced cardiovascular disease. Protection against space radiation is required for long-duration missions in space, including a manned-trip to Mars.

StemoniX partnered with Humanetics for the research. StemoniX is a Minnesota company with a microHeart Assay Ready platform containing functional human heart tissue derived from induced pluripotent stem cells (iPSCs). These heart cells are organized in screening plates simulating tissue architecture and “beat” rhythmically in culture, reproducing human cardiovascular biology. BIO 300 protected the microHeart cells from various doses of the mixed-field radiation, enhancing their survival following mission-relevant doses of radiation. Cardiac radioprotection was also demonstrated in a separate study using proton radiation.

The data were recently presented at the NASA Human Research Program conference in Galveston, Texas by Michael Kaytor, vice president of research and development at Humanetics. “The response from NASA has been positive and encouraging,” said Kaytor. “Our ultimate goal is to make BIO 300 available for astronauts, enabling exploration deeper into the solar system.”

BIO 300 is also being developed for other uses, including in cancer radiation treatment to protect normal tissues from harm and for military use to protect warfighters in areas of nuclear or radiological concern. BIO 300 is currently being evaluated in a multi-site clinical trial involving patients receiving radiation and chemotherapy for non-small cell lung cancer.

For more information: www.humaneticscorp.com

Related Content

Icosapent Ethyl (Vascepa) significantly Reduces Revascularizations in Statin Patients in the REDUCE-IT REVASC analyses presented as a late-breaking study at SCAI 2020. Photo by Dave Fornell

Icosapent Ethyl (Vascepa) significantly reduces revascularizations in statin patients based on data from the REDUCE-IT REVASC analyses, presented as a late-breaking study at SCAI 2020. Photo by Dave Fornell

News | Pharmaceuticals | May 17, 2020
May 17, 2020 – Patients with high lipid levels have an increased risk for ischemic events, despite statin therapy.
Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial. #ACC20 #ACC2020

Scott Wright, M.D., Mayo Clinic, presenting the results at ACC on the two-dose a year LDL-lowering drug inclisiran, which had a significant reduction in LDL in the ORION Trial.

News | Pharmaceuticals | March 28, 2020 | Dave Fornell, Editor
March 28.
The U.S. Food and Drug Administration (FDA) approved Esperion's bempedoic acid (Nexletor) tablet, an oral, once-daily, non-statin low-density lipoprotein cholesterol (LDL-C) lowering medicine. The drug is indicated as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of LDL-C. 
Feature | Pharmaceuticals | February 24, 2020
February 24, 2020 — The U.S.
This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.

This image shows the cardiac muscle fibers of a fruit fly under magnification. Iowa State University researchers have found a way to restore the strength and regularity of cardiac muscles in aging fruit flies. Photo by Hua Bai, Iowa State University.

News | Pharmaceuticals | January 09, 2020
January 9, 2020 – Researchers may have discovered a way to turn back the clock on aging heart muscles in fruit flies,
 Christie Ballantyne

Dr. Christie Ballantyne, professor of medicine and chief of the section of cardiology at Baylor College of Medicine

News | Pharmaceuticals | December 30, 2019
December 30, 2019 — A drug therapy targeting the production of a protein produced by the liver has led to sustained a
Vascepa pill contains a concentrated form of fish oil, icosapent ethyl, indication for prevention. The U.S. Food and Drug Administration (FDA) Dec. 13, 2019, approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive therapy to reduce the risk of cardiovascular events in adults with elevated triglyceride levels.
Feature | Pharmaceuticals | December 16, 2019 | Dave Fornell, Editor
The U.S. Food and Drug Administration (FDA) approved the use of Vascepa (icosapent ethyl) capsules as an adjunctive...
Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after biologic therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after psoriasis biologic drug therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

 

Feature | Pharmaceuticals | July 31, 2019
July 31, 2019 — Researchers found anti-inflammatory drug therapies used to treat moderate to severe psoriasis can sig
Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...